Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury

Summary

The purpose of this study is to determine if there is an excess risk of acute kidney injury (AKI) with Serotonin-norepinephrine reuptake inhibitors (SNRIs) as compared to Selective serotonin reuptake inhibitors (SSRIs), two classes of medication used for the treatment of depression.

Conditions

• Depression
• Acute Kidney Injury

Interventions

DRUG

Duloxetine

Current exposure to Duloxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.

DRUG

Venlafaxine

Current exposure to Venlafaxine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.

DRUG

Desvenlafaxine

Current exposure to Desvenlafaxine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.

DRUG

Citalopram

Current exposure to Citalopram will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.

DRUG

Escitalopram

Current exposure to Escitalopram will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.

DRUG

Fluoxetine

Current exposure to Fluoxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.

DRUG

Fluvoxamine

Current exposure to Fluvoxamine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.

DRUG

Paroxetine

Current exposure to Paroxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.

DRUG

Sertraline

Current exposure to Sertraline will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.

Sponsors & Collaborators

• Drug Safety and Effectiveness Network, Canada

  collaborator OTHER

• Canadian Institutes of Health Research (CIHR)

  collaborator OTHER_GOV

• Canadian Network for Observational Drug Effect Studies, CNODES

  lead OTHER

Principal Investigators

• Pierre Ernst, MD, MSc · Lady Davis Institute for Medical Research, Jewish General Hospital - McGill University

Eligibility

Min Age

12 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2013-06-30

Primary Completion

2014-12-31

Completion

2014-12-31

Countries

• Canada

Study Locations